Methylprednisolone

Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s. Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was successful in treating COVID-19-associated pneumonia in one patient with long-term immunosuppression. The efficacy of methylprednisolone in novel coronavirus pneumonia is being investigated further in clinical trials. It is grouped under the following drug class(es): Corticosteroids, Immunosuppressants, Ophthalmic corticosteroids, Steroids and Systemic corticosteroids. Its therapeutic use is listed as anti-asthmatic agents, anti-inflammatories, antirheumatic agents, dermatologicals and osteoarthritis agents. The directory classifies it as a commercial API with a semi-synthetic source/manufacturing origin. Other names for this substance include Medrone, Medrate and Urbason. Its PubChem CID is 6741.

CAS No 83-43-2
Molecular Formula C22H30O5
Molecular Weight 374.50 g/mol
Synonyms (6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one

Frequently Asked Questions